Vol. 13. Núm. 25.
Páginas 1429.e1-1429.e3 (Febrero 2021)

Casos clínicos
Paciente gran superviviente con cáncer de cabeza y cuello metastásico y tratamiento con inmunoterapia

A. OlivaresE. del BarcoL. BellidoB. CigarralJ. ClarosE. EscaleraB. BarriosD. CasadoL. FigueroA. LópezE. TeránJ.J. Cruz
Doi : https://10.1016/j.med.2021.02.010
Opciones

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
L.C. Iglesias
202102260708052158
202102260708052159
, V. Arrazubi, N. Baste, A. Carral, B. Cirauqui, Y. Escobar, et al.
SEOM clinical guidelines for the treatment of head and neck cáncer (2017).
Clin Transl Oncol., (2018), 20 pp. 75-83
[2]
J.P. Pignon
2021022607080521510
2021022607080521511
, A. Le Maître, E. Maillard, J. Bourhis.
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17346 patients.
Radiother Oncol., (2009), 92 pp. 4-14
[3]
J.B. Vermorken
2021022607080521512
2021022607080521513
, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, S. Rottey, et al.
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med., (2008), 359 pp. 1116-1127
[4]
R. Hitt
2021022607080521514
2021022607080521515
, J.J. Grau, A. López-Pousa, A. Berrocal, C. García-Girón, A. Irigoyen, et al.
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Ann Oncol., (2014), 25 pp. 216-225
[5]
M.G. Ghi
2021022607080521516
2021022607080521517
, A. Paccagnella, D. Ferrari, P. Foa, D. Alterio, C. Codecá, et al.
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Ann Oncol., (2017), 28 pp. 2206-2212
[6]
R. Hitt
2021022607080521518
2021022607080521519
, A. Irigoyen, H. Cortes-Funes, J.J. Grau, J.A. García-Sáenz, J.J. Cruz-Hernandez, Spanish Head and Neck Cancer Cooperative Group (TTCC).
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Ann Oncol., (2012), 23 pp. 1016-1022
[7]
R.L. Ferris
2021022607080521520
2021022607080521521
, G. Blumenschein, J. Fayette, J. Guigay, D. Colevas, L. Licitra, et al.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
N Engl J Med., (2016), 375 pp. 1856-1867
[8]
B. Burtness
2021022607080521522
2021022607080521523
, K.J. Harrington, R. Greil, D. Souliéres, M. Tahara, G. de Castro, et al.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet., (2019), 394 pp. 1915-1928
[9]
P.M. Som
2021022607080521524
2021022607080521525
, H.D. Curtin, A.A. Mancuso.
An imaging- based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications.
Arch Otolaryngol Head Neck Surg., (1999), 125 pp. 388-396
[10]
B. Tantiwongkosi
2021022607080521526
2021022607080521527
, F. Yu, A. Kanard, F.R. Miller.
Role of 18F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma.
World J Radiol., (2014), 6 pp. 177-191